• Originator MedImmune
• Developer AIO Studien gGmbH; AstraZeneca; AVEO Oncology; Big Ten Cancer Research Consortium; Biocompatibles International; Canadian Cancer Trials Group; Cancer Research UK; Case Comprehensive Cancer Center; Celgene Corporation; Celgene International SARL; Centre hospitalier de l'Universite de Montreal; Centre Leon Berard; Charite - Universitatsmedizin Berlin; Childrens Hospital Los Angeles; Daiichi Sankyo Company; Dana-Farber Cancer Institute; Eli Lilly and Company; European Network of Gynaecological Oncological Trial Groups; Fondazione IRCCS Istituto Nazionale dei Tumori; Gradalis; Grand Hopital de Charleroi; Grupo Espanol de Tumores Neuroendocrinos; GSK; Gustave Roussy; Immunocore; Innate Pharma; Institut Claudius Regaud; Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori; Jules Bordet Institute; Juno Therapeutics; Kyoto Breast Cancer Research Network; Ludwig Institute for Cancer Research; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; Mirati Therapeutics; Myriad Genetic Laboratories; National Cancer Institute (USA); National Health and Medical Research Council; NHS Greater Glasgow and Clyde; Nordic Society of Gynaecological - Clinical Trial Unit; Northwestern University; Pharmacyclics; Radboud University; Samsung Medical Center; Spanish Oncology Genito-Urinary Group; Swiss Group for Clinical Cancer Research; SWOG; UNC Lineberger Comprehensive Cancer Center; Undisclosed; UNICANCER; University College London; University Health Network; University of Colorado at Denver; University of Kansas Medical Center; University of Maryland Greenbaum Cancer Center; University of Southern California; University of Sydney; University of Texas M. D. Anderson Cancer Center; VentiRx Pharmaceuticals; Washington University School of Medicine; Yale University; Yonsei University College of Medicine
• Class Antineoplastics; Immunotherapies; Monoclonal antibodies
• Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants

• Orphan Drug Status

  Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  Yes - Biliary cancer; Small cell lung cancer; Liver cancer
• New Molecular Entity Yes

Highest Development Phases

• Marketed Non-small cell lung cancer; Small cell lung cancer
• Registered Biliary cancer; Bladder cancer; Endometrial cancer; Liver cancer; Urogenital cancer
• Phase III Cervical cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Malignant-mesothelioma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
• Phase II/III Pancreatic cancer
• Phase II Acute myeloid leukaemia; Brain metastases; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Gallbladder cancer; Germ cell cancer; Glioblastoma; HER2 negative breast cancer; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Oropharyngeal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Uterine cancer
• Phase I/II Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Haematological malignancies; Lung cancer; Lymphoma; Peripheral T-cell lymphoma; Renal cancer
• No development reported CNS cancer; Gastrointestinal cancer; Lymphoproliferative disorders; Thyroid cancer; Vulvovaginal cancer

Most Recent Events

• 24 Jun 2025 AstraZeneca terminates a first-in-human phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France and USA (IV), early due to lack of efficacy and absence of biomarker evidence of MEDI 9253's impact on the tumours (NCT04613492)
• 01 Jun 2025 Updated efficacy data from the phase III MATTERHORN trial in Oesophageal cancer and Gastric cancer released by AstraZeneca
• 28 May 2025 AstraZeneca plans a phase III ALBORAN trial for Small cell lung cancer (Second-line therapy or greater) in Spain (IV) (NCT06992609)